COMMUNIQUÉS West-GlobeNewswire

Cytori Cell Therapy™ Clinical Trial Results in Crohn’s Disease
31/01/2019
80% of Treated Patients with Clinical Response at 48 weeks, Published in Gastroenterology SAN DIEGO, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announces the publication of results from a [...]
Agritek Holdings, Inc. Announces Partnership Agreement with Colorado's Top Selling Cannabis Edibles Brand, Mountain High Suckers, for Puerto Rico Through Exclusive Licensee 1919 Clinic
31/01/2019
LOS ANGELES, CA, Jan. 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Agritek Holdings, Inc. (OTC PINK: AGTK) www.AgritekHoldings.com , a fully integrated, active cannabis real estate investor and brand licensor for the [...]
Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1
31/01/2019
First commercially available, automated single-cell analysis application to enable co-detection of cellular protein and RNA expression using microfluidics technology SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE [...]
CLS Holdings’ Oasis Dispensary Featured in February 2019 Edition of A&E Magazine as “Best Dispensary for Pot Pros”
31/01/2019
LAS VEGAS, Jan. 31, 2019 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc.’s (OTCQB: CLSH)(CSE: CLSH.U),“CLS”, Oasis dispensary is featured in the February 2019 edition of A&E Magazine as the “Best Dispensary for Pot Pros [...]
CareKinesis, a subsidiary of Tabula Rasa HealthCare, Signs New PACE Client in Arkansas
31/01/2019
Programs of All-inclusive Care for the Elderly Expanding in the State of Arkansas MOORESTOWN, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC) , a healthcare technology company [...]
HealthEC Awarded 2019 Best in KLAS Designation for Population Health
31/01/2019
Firm to be recognized at the KLAS Awards Reception during HIMSS19 in Orlando, Florida EDISON, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- HealthEC, LLC, an end-to-end provider of population health management solutions, [...]
Anavex Life Sciences to Announce Fiscal 2019 First Quarter Financial Results on Thursday, February 7th, 2019
31/01/2019
Conference Call and Webcast To be Held Thursday, February 7, 2019 4:30pm Eastern Time NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage [...]
Chiesi USA, Inc. Receives Top Employer in the US Certification for 2019
31/01/2019
Top Employer Institute recognizes Chiesi USA for the fourth consecutive year CARY, N.C., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee) announced today that the company has been named as a Top Employer [...]
Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
31/01/2019
NEW YORK and CLEVELAND, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today [...]
Novo Nordisk A/S - Share repurchase programme
31/01/2019
Bagsværd, Denmark, 31 January 2019 - On 5 November 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™
31/01/2019
PHILADELPHIA, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the [...]
Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
31/01/2019
Invitation-only breakfast event sponsored by Onconova Therapeutics will also be webcast, beginning at 8:00 a.m. EST NEWTOWN, Pa., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) , a Phase 3 [...]
Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer’s Disease
31/01/2019
Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the toxic oligomer with extraordinary precision TORONTO and CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- ProMIS [...]
Nash Pharmaceuticals to Present Pre-Clinical Data on Non-Alcoholic Fatty Liver Disease at 2nd Global NASH Congress in London, UK
31/01/2019
VANCOUVER, British Columbia, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: BTH ) (the “ Company ” or “Nash Pharma”) is pleased to [...]
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019
31/01/2019
CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company [...]
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 7, 2019
31/01/2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV [...]
Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals
31/01/2019
Fortress-founded Caelum Biosciences to receive $60 million in a strategic equity investment and option fee Alexion has option to acquire Caelum Biosciences based on Phase 2 data NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE [...]
Quotient Limited Provides an Update on Extended Immunohematology Microarray Performance and on the Commencement of the Initial Serological Disease Screening Field Trial together with Third Quarter Fiscal 2019 Results
31/01/2019
Development data provides positive results for extended IH microarray panel Field trial for initial Serological Disease microarray panel has commenced Reagent revenue growth of 15% in the quarter and 12% year to date [...]
Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers
31/01/2019
- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition - - Achillion planning Investigational New Drug (IND) submission in fourth quarter of 2019 - NEW HAVEN, Conn., Jan. 31, 2019 ( [...]

Pages